Related Experiment Video
Updated: May 17, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Towards hepatitis C elimination with integrated risk-based screening and decentralized care in Taiwan
Yen-Po Yeh1,2,3, Abbie Ting-Yu Lin4, Wei-Wen Su5
1Changhua County Public Health Bureau, Changhua, Taiwan.
Insights
Taiwan
Area of Science:
- Hepatology and Viral Hepatitis Research
- Public Health Interventions
- Epidemiology of Infectious Diseases
Background:
- Chronic hepatitis C virus (HCV) infection is a significant global health issue, necessitating effective elimination strategies.
- Taiwan faces a considerable HCV burden, with regional variations in prevalence, such as 4.3% in Changhua County prior to intervention.
- Achieving global HCV elimination targets requires innovative and efficient public health programs.
Purpose of the Study:
- To evaluate the impact of the Changhua Integrated Program to Stop Hepatitis C Infection (CHIPS-C) on HCV care cascade performance.
- To assess the effectiveness of a decentralized, risk-targeted approach to HCV screening and treatment.
- To determine if the CHIPS-C program can accelerate progress towards World Health Organization HCV elimination goals.
Main Methods:
- A population-based cohort study comparing HCV care cascade metrics before and after the CHIPS-C program implementation in Changhua County.
- Utilized individual-level data to analyze changes in screening coverage, diagnosis rates, and treatment completion.
- Employed model-based projections to estimate the long-term impact on HCV-related liver cancer and mortality.
Main Results:
- CHIPS-C significantly increased screening coverage from 53.7% to 90.2%.
- The program improved efficiency, diagnosing similar numbers of infections with fewer individuals screened.
- Adjusted treatment completion rates dramatically increased from 38.7% to 83.9% post-implementation.
- Streamlined testing and coordinated care were key drivers of these improvements.
Conclusions:
- The CHIPS-C program demonstrates a highly effective model for improving HCV care cascade outcomes through integrated, risk-based strategies.
- This micro-elimination approach significantly enhances screening and treatment completion, accelerating progress towards HCV elimination targets.
- The findings provide a scalable blueprint for enhancing HCV elimination efforts in diverse healthcare settings worldwide.
Abstract:
Chronic hepatitis C virus (HCV) infection remains a major cause of liver disease worldwide and requires effective strategies to achieve elimination targets. Taiwan has a substantial HCV burden, with prevalence varying by region; in Changhua County, prevalence was 4.3% before large-scale intervention. In 2019, Changhua launched a county-wide micro-elimination program-the Changhua Integrated Program to Stop Hepatitis C Infection (CHIPS-C)-which combined existing population screening with targeted outreach to higher-risk groups and decentralized delivery of curative direct-acting antiviral (DAA) treatment. Using individual-level data from a population-based cohort, we compared care cascade performance before and after CHIPS-C implementation. The program was associated with increased screening coverage (53.7% to 90.2%) and fewer individuals screened to achieve similar numbers of diagnosed infections. Improvements were driven by streamlined confirmatory testing and coordinated care delivery. Here we show that CHIPS-C substantially increased the adjusted treatment completion rate (83.9% vs 38.7% before implementation). Model-based projections indicate that these gains could reduce HCV-related liver cancer and mortality to levels meeting World Health Organization elimination targets by 2030. These findings demonstrate that integrating risk-based targeting with existing health systems can markedly improve efficiency and outcomes, providing a scalable model for accelerating HCV elimination in diverse settings.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
